Clinical Trial

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

Name: Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment — clinical trial record (NCT05484375)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

to evaluate the efficacy and safety of toripalimab and capecitabine maintenance therapy in patients with metastatic nasopharyngeal carcinoma (NPC) after first-line gemcitabine/cisplatin combined with toripalimab.

Trial Details

NCT Number	NCT05484375
Lead Sponsor	Affiliated Cancer Hospital & Institute of Guangzhou Medical University Collaborators: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Hunan Cancer Hospital
Conditions	Metastatic Nasopharyngeal Carcinoma
Enrollment	40 participants
Start Date	2022-09
Primary Completion	2027-09 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2022-08-02